Search results for "Prothrombin"

showing 10 items of 69 documents

Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting

1992

Patients with intracoronary stent implantation are treated with aggressive anticoagulant and antiplatelet therapy consisting of high-dose heparin, phenprocoumon, acetylsalicylic acid, dipyridamole, and the infusion of dextran to prevent a subacute thrombotic occlusion of the stented segment. In an effort to optimize this treatment by reducing both imminent bleeding complications and subacute thrombotic occlusion, the concentrations of prothrombin fragment 1 + 2 (F 1 + 2) were determined after intracoronary Palmaz-Schatz stent implantation in 19 consecutive patients. The F 1 + 2 concentrations after stent implantation and before the initiation of oral anticoagulant therapy (OAT) were 0.35 nm…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentUrologyAdministration OralPhenprocoumonmedicineHumansAngioplasty Balloon CoronaryAgedChemotherapyHeparinbusiness.industryPROTHROMBIN FRAGMENT 1.2AnticoagulantAnticoagulantsHematologyGeneral MedicineHeparinMiddle AgedThrombophlebitismedicine.diseaseThrombosisPeptide FragmentsDipyridamoleHeart Valve ProsthesisAnesthesiaPhenprocoumonFemaleProthrombinStentsPulmonary EmbolismComplicationbusinessmedicine.drugAnnals of Hematology
researchProduct

Association of Inflammation Markers with Impaired Insulin Sensitivity and Coagulative Activation in Obese Healthy Women

2003

Abstract Insulin resistance is associated with a low chronic inflammatory state. In this study we investigated the relationship between impaired insulin sensitivity and selected markers of inflammation and thrombin generation in obese healthy women. We examined 32 healthy obese women (body mass index ≥ 28), with normal insulin sensitivity (NIS, n = 14) or impaired insulin sensitivity (n = 18), and 10 nonobese women (body mass index < 25). Impaired insulin sensitivity patients had significantly higher levels of C-reactive protein (CRP), TGF-β1, plasminogen activator inhibitor-1 (PAI-1), activated factor VII (VIIa), and prothrombin fragment 1 + 2 (F1 + 2) compared with either control s…

Adultmedicine.medical_specialtyobesityEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryPopulationInflammationFactor VIIaBiologyBiochemistryEndocrinologyInsulin resistanceTransforming Growth Factor betaInternal medicineinsulin resistancePlasminogen Activator Inhibitor 1medicineHumansProtein PrecursorseducationBlood CoagulationPancreatic hormoneeducation.field_of_studyInsulinBiochemistry (medical)ThrombinMiddle Agedmedicine.diseaseObesityPeptide FragmentsC-Reactive ProteinEndocrinologyhemostasis; inflammation; insulin resistance; obesityinflammationhemostasisFemaleProthrombinmedicine.symptomBody mass indexPlasminogen activatorBiomarkers
researchProduct

A Rapid and Sensitive Strip-Based Quick Test for Nerve Agents Tabun, Sarin, and Soman Using BODIPY-Modified Silica Materials

2016

Test strips that in combination with a portable fluorescence reader or digital camera can rapidly and selectively detect chemical warfare agents (CWAs) such as Tabun (GA), Sarin (GB), and Soman (GD) and their simulants in the gas phase have been developed. The strips contain spots of a hybrid indicator material consisting of a fluorescent BODIPY indicator covalently anchored into the channels of mesoporous SBA silica microparticles. The fluorescence quenching response allows the sensitive detection of CWAs in the mu g m(-3) range in a few seconds.

Boron CompoundsSarinSilicon dioxideSomanAnalytical chemistrynerve gases010402 general chemistry01 natural sciencesCatalysischemistry.chemical_compoundSomanQUIMICA ANALITICAmedicineChemical Warfare AgentsTabunNerve agenthybrid sensor materialsChromatography010405 organic chemistryOrganic ChemistryQUIMICA INORGANICAGeneral ChemistrySilicon DioxideFluorescenceSarinOrganophosphates0104 chemical scienceschemistrychemical warfare agentstest strip analysisProthrombin TimefluorescenceBODIPYMesoporous materialNerve Agentsmedicine.drug
researchProduct

Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma

2005

Thrombosis is the most frequent complication and the second cause of death in patients with malignant disease. Primary central nervous system non-Hodgkin's lymphoma represents a rare pathology. Resistance to APC is usually linked to a factor V (FV) gene mutation changing an Arg 506 to a Gln in the APC cleavage site.In our study, we aimed at investigating the presence of activated protein C resistance (APC-r) and other markers of hypercoagulability in 25 selected patients with a diagnosis of primitive cerebral lymphoma who had suffered from an ischemic episode of TIA and/or stroke.25 selected patients with a diagnosis of primitive cerebral lymphoma and 50 healthy subjects acted as control gr…

Brain NeoplasmsLymphoma Non-HodgkinFactor VPeptide FragmentsBrain NeoplasmStrokePhenotypePeptide FragmentIschemic Attack TransientCase-Control StudiesMutationPlasminogen Activator Inhibitor 1HumansProthrombinCase-Control StudieBlood CoagulationBiomarkersHumanActivated Protein C Resistance
researchProduct

ProC Global: the first functional screening assay for the complete protein C pathway.

1997

Abstract In clinical practice, venous thromboembolic complications are much more frequent than bleeding disorders. In fact, disturbances within the protein C pathway due to coagulation factor V (FV) Leiden mutation and deficiency of protein C or protein S are the most frequent abnormalities in hereditary thrombophilia. Furthermore, acquired dysfunctions of the protein C system may predispose the single individual to an increased thrombotic risk. A routine-suited screening assay that would allow the monitoring of the proper interplay of factors in the protein C pathway could add an important factor to the basic coagulation profile. This consists of the prothrombin time and of the activated p…

Clinical BiochemistryBlood DonorsSensitivity and SpecificityProtein SProtein SProtein C deficiencyReference ValuesMedicineHumansMass ScreeningProtein S deficiencyProthrombin timemedicine.diagnostic_testbiologybusiness.industryBiochemistry (medical)Factor VFactor VProtein C DeficiencyReproducibility of ResultsThrombosisBlood Coagulation Disordersmedicine.diseaseImmunologyMutationbiology.proteinCancer researchPartial Thromboplastin TimeDisease SusceptibilityReagent Kits DiagnosticActivated protein C resistancebusinessProtein CPartial thromboplastin timemedicine.drugProtein CClinical chemistry
researchProduct

Successful management of heparin-induced thrombocytopenia using argatroban in a very old woman: a case report.

2012

Thrombosis due to heparin-induced thrombocytopenia (HIT) is rare but has a severe prognosis. Its management is not always easy, particularly in old patients with renal insufficiency. A 95-year-old woman was hospitalized for dyspnea. Curative treatment with unfractionated heparin was started because pulmonary embolism was suspected. Disseminated intravascular coagulation was then suspected because of thrombocytopenia, hypoprothrombinemia, hypofibrinogenemia, and a positive ethanol gelation test. The first immunoassay for HIT was negative. On the 12th day of hospitalization, bilateral cyanosis of the toes occurred associated with recent deep bilateral venous and arterial thrombosis at duplex …

Disseminated intravascular coagulationmedicine.medical_specialtybusiness.industrylcsh:Rlcsh:MedicineCase ReportGeneral MedicineHeparinHypofibrinogenemiamedicine.diseaseThrombosisArgatrobanSurgeryPulmonary embolismHeparin-induced thrombocytopeniamedicineHypoprothrombinemiabusinessmedicine.drugCase reports in medicine
researchProduct

Oxcarbazepine does not affect the anticoagulant activity of warfarin.

1992

The possible interaction of the antiepileptic drug oxcarbazepine (OCBZ) on the anticoagulant effect of warfarin was investigated in 10 healthy male volunteers. After reaching steady-state conditions by repeated administration of warfarin, the prothrombin time (Quick value) was assessed before and after single (600 mg) and multiple dosing (450 mg twice daily in 1 week) of OCBZ. In 7 of the 10 volunteers with evaluable data, the prothrombin time was not significantly different (paired t test) from baseline either after single (p = 0.299) or repeated dosing (p = 0.333), indicating that OCBZ does not interact to any relevant extent with the hypothrombinemic effect of warfarin.

DrugAdultMalemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentOxcarbazepinePharmacologymedicineHumansDrug InteractionsOxcarbazepineBlood Coagulationmedia_commonProthrombin timeChemotherapymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnticoagulantWarfarinDose–response relationshipAnticonvulsantCarbamazepineNeurologyAnesthesiaProthrombin TimeAnticonvulsantsNeurology (clinical)Warfarinbusinessmedicine.drugEpilepsia
researchProduct

Role of prothrombotic polymorphisms in successful or unsuccessful aging.

2011

The study of the genetic profile of centenarians aims to identify the genes and allelic variants which may influence a greater life expectancy and that can be considered as predisposing factors associated to the aging diseases, such as Alzheimer. Centenarians, that represent a cohort of selected survivors, show an hypercoagulability state characterised by striking signs of high coagulation enzyme activity, as directly assessed by the tested higher plasma level of some important factors involved in the haemostasis balance. Anyway, these individuals seem to have a reduced susceptibility to dementia, as well as to cardiovascular events. In this study we analyze the frequencies of Leiden Factor…

GerontologyMaleAging.media_common.quotation_subjectDiseaseBioinformaticsLeiden factor V; Prothrombin; Nonagenarians; Alzheimer disease; Aging.Polymorphism (computer science)Alzheimer DiseasemedicineDementiaHumansNonagenarianAlleleAllelesmedia_commonAgedSettore MED/04 - Patologia GeneralePolymorphism GeneticSuccessful agingbusiness.industryALZHEIMER’S DISEASEagingLongevityFactor Vmedicine.diseaseCase-Control StudiesCohortFemaleProthrombinGeriatrics and GerontologyAlzheimer's diseasebusinessGerontologyLeiden Factor V
researchProduct

Prothrombinase-Induced Clotting Time Assay for Determination of the Anticoagulant Effects of Unfractionated and Low-Molecular-Weight Heparins, Fondap…

2008

The prothrombinase-induced clotting time assay (PiCT, Pentapharm, Basel, Switzerland) is a clotting assay sensitive to factor Xa and factor IIa inhibitors. It is based on the addition of factor Xa and snake venom RVV-V (Russell viper venom factor V activator) specifically activating factor V and phospholipids to platelet-poor plasma. Following an incubation time, the mixture is recalcified and the clotting time is determined. An almost linear dose-response and high sensitivity of the assay for unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), r-hirudin, and argatroban was found. Fondaparinux showed a nonlinear dose-response. By using ex vivo samples, the following Pearson…

HeparinChemistryHirudinGeneral MedicineHeparin Low-Molecular-WeightPharmacologyFondaparinuxSensitivity and SpecificityFondaparinux SodiumArgatrobanThromboplastinThrombinFibrinolytic AgentsFondaparinuxBiochemistryClotting timePolysaccharidesProthrombinasemedicineHumansBlood Coagulation Testsmedicine.drugDiscovery and development of direct thrombin inhibitorsAmerican Journal of Clinical Pathology
researchProduct

CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models

2021

BACKGROUND: CD248 is a pro-inflammatory, transmembrane glycoprotein expressed by vascular smooth muscle cells (VSMC), monocytes/macrophages, and other cells of mesenchymal origin. Its distribution and properties are reminiscent of those of the initiator of coagulation, tissue factor (TF). OBJECTIVE: We examined whether CD248 also participates in thrombosis. METHODS: We evaluated the role of CD248 in coagulation using mouse models of vascular injury, and by assessing its functional interaction with the TF-factor VIIa (FVIIa)-factor X (FX) complex. RESULTS: The time to ferric chloride-induced occlusion of the carotid artery in CD248 knockout (KO) mice was significantly longer than in wild-typ…

InflammationFactor VIIa030204 cardiovascular system & hematologyInferior vena cavaArticleThromboplastin03 medical and health sciencesTissue factorchemistry.chemical_compoundMice0302 clinical medicineThrombinTissue factor pathway inhibitorAntigens CDAntigens NeoplasmmedicineAnimalsHumansMice KnockoutVenous Thrombosismedicine.diagnostic_testFactor XHematologyCoagulationchemistrymedicine.veinCancer researchProthrombin Timemedicine.symptommedicine.drugPartial thromboplastin time
researchProduct